Key Developments: Smith & Nephew PLC (SNN.N)

SNN.N on New York Stock Exchange

59.47USD
24 May 2013
Price Change (% chg)

$0.08 (+0.13%)
Prev Close
$59.39
Open
$59.11
Day's High
$59.53
Day's Low
$58.94
Volume
10,925
Avg. Vol
13,161
52-wk High
$60.30
52-wk Low
$44.87

Search Stocks

Latest Key Developments (Source: Significant Developments)

Smith & Nephew PLC to Acquire Adler Mediequip Private Limited and Indian Trauma Business
Thursday, 2 May 2013 

Smith & Nephew PLC announced that it has signed an agreement to acquire Adler Mediequip Private Limited and with it, the brands and assets of Sushrut Surgicals Private Limited, operating in mid-tier, orthopaedic trauma products for the India market. The transaction is expected to complete upon the satisfaction of customary conditions. The terms were not disclosed. The acquisition gives Smith & Nephew a platform to provide and develop products for the mid-tier market in India and for export.  Full Article

Smith & Nephew PLC Proposes Final Dividend
Thursday, 7 Feb 2013 

Smith & Nephew PLC announced that a final dividend for 2012 of $0.1620 per ordinary share has been proposed by the Board and will be payable, subject to shareholder approval, on May 8, 2013 to shareholders whose names appear on the register at the close of business on April 19, 2013. The sterling equivalent per ordinary share will be set following the record date.  Full Article

Smith & Nephew PLC Completes Healthpoint Acquisition
Monday, 24 Dec 2012 

Smith & Nephew PLC announced the completion of the acquisition of substantially all the assets of Healthpoint Biotherapeutics (Healthpoint). The purchase price of $782 million in cash has been financed from Smith & Nephew's existing cash resources and bank facilities.  Full Article

Biotec Pharmacon ASA's Subsidiary Starts Cooperation with Smith & Nephew PLC
Friday, 21 Dec 2012 

Biotec Pharmacon ASA announced that its wholly owned subsidiary Biotec BetaGlucans AS has signed an agreement with Smith & Nephew PLC to cooperate on a market evaluation of Woulgan Biogel. Woulgan Biogel is a new bioactive treatment for use on chronic wounds. It has successfully completed phase II trials and is expected to attain CE mark in 2013. At this point Biotec BetaGlucans and Smith & Nephew will conduct a market evaluation of the product in a limited number of centers across Europe. Until and during the trial period, S&N will have an exclusive, non-transferable, non-sublicensable right to the BBG Technology linked to fulfillment of agreed commitments between the Parties.  Full Article

Smith & Nephew PLC's Subsidiary To Acquire Healthpoint Biotherapeutics
Wednesday, 28 Nov 2012 

Smith & Nephew PLC announced that it has entered into an agreement through its subsidiaries to acquire substantially all the assets of Healthpoint Biotherapeutics, company into in bioactive debridement, dermal repair and regeneration wound care treatments, for $782 million in cash.  Full Article

Smith & Nephew PLC Announces Directorate Change
Monday, 17 Sep 2012 

Smith & Nephew PLC announced that Adrian Hennah, Chief Financial Officer, will be leaving the Company at the end of December 2012 to become Chief Financial Officer at Reckitt Benckiser Group plc. The search for a successor to Adrian is underway, and a further announcement will be made in due course.  Full Article

Smith & Nephew PLC Announces Interim Dividend
Thursday, 2 Aug 2012 

Smith & Nephew PLC announced that the Board has increased the level of the 2012 interim dividend payment by 50% to 9.9¢ per share (49.5¢ per ADS), compared with 6.6¢ last year. This will be paid on October 30, 2012 to shareholders on the register at the close of business on October 12, 2012.  Full Article

Smith & Nephew plc Acquires Privately-Held TENET Medical Engineering, Inc.
Thursday, 23 Jun 2011 

Smith & Nephew plc announced the acquisition of privately held, Calgary, Alberta based TENET Medical Engineering, Inc. TENET markets edge technology in the area of patient positioning such as intuitive positioning controls, increased versatility, adjustability and stability, global compatibility and fully integrated systems used in arthroscopic surgery. Terms of the agreement were not disclosed.  Full Article

Smith & Nephew plc's Endoscopy Division Smith & Nephew, Inc. Awarded $85 Million In Patent Infringement Case Against Arthrex, Inc.
Thursday, 23 Jun 2011 

Smith & Nephew, Inc., Endoscopy Division, a subsidiary of Smith & Nephew plc, announced that the jury in United States District Court in Oregon found in Smith & Nephew's favor that Arthrex, Inc., (Naples, Fla.) was guilty of infringing U.S. Patent 5,601,557, which is exclusively licensed to Smith & Nephew. The jury found that Arthrex's Bio-SutureTak, PEEK SutureTak, PushLock and Bio-PushLock suture anchors infringe the patent and awarded Smith & Nephew $85 million for Arthrex's past infringement activities.  Full Article

  • Previous
  • Next

Smith & Nephew PLC News

UPDATE 1-Smith & Nephew unveils $300 mln share buyback

* $300 mln buyback planned alongside continued investment, M&A

» More SNN.N News

Market Views

» More SNN.N Market Views

Earnings vs. Estimates

» More Financials
Search Stocks